Atom Therapeutics to Present at BIO CEO & Investor Conference on February 6, 2023, at the Marriott Marquis, New York City

PRESS RELEASE

Atom Therapeutics to Present at BIO CEO & Investor Conference on February 6, 2023, at the Marriott Marquis, New York City

Company plans to launch Phase 2b/3 clinical trial of much needed new treatment for gout

Jiangsu, China—February 1, 2023 – Atom Therapeutics, a clinical stage biotechnology company developing new treatments for inflammatory and metabolic diseases, announced today that the company will make an in-person presentation, updating investors on its clinical pipeline, at the annual BIO CEO & Investor Conference, February 6-9, 2023, at the Marriott Marquis, New York City. The conference will include in-person meetings February 6-7 followed by virtual partnering Feb 8-9.

Roy J. Wu, Atom’s Senior Vice President of Global Business Development, will make his presentation February 6, Monday at 4:30 pm, in the Palace room at the Marriott Marquis.

Atom’s lead product, ABP-671, is an oral, small molecule URAT1 inhibitor for treatment of chronic gout. The drug is designed to reduce excessive levels of uric acid in the blood, a condition called hyperuricemia, which is the cause of gout and its characteristic painful and debilitating flare-ups. In a Phase 2a trial, ABP-671 was well tolerated and reduced uric acid levels below the threshold for hyperuricemia. The company expects to enter a Phase 2b/3 clinical trial soon.

Gout is one of the most common types of inflammatory arthritis affecting more than 55 million people worldwide. The disease has a large and growing patient population in the U.S., Europe, Asia and Latin America. The painful gout flare-ups, concentrated primarily in the joints of lower extremities, occur when uric acid in the blood exceeds levels greater than 7 mg/dL, the threshold for hyperuricemia. Failure to maintain healthy levels of uric acid can cause permanent joint damage as well as other complications such as heart, kidney and eye diseases.

About Atom Therapeutics

Hangzhou Atom Therapeutics Co., Ltd., is a fast-growing innovative drug company focused on development of best in class small molecule therapeutics for treatment of inflammatory and metabolic diseases. The company’s lead product, ABP-671, is in late stage clinical development for treatment of chronic gout. For more information please visit: https://atombp.us/.